IMBiologics
PublicIMBiologics is now publicly traded
The data on this page reflects IMBiologics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Jul 24, 2023
Total Funding Raised
$19.14M
Company Overview
IMBiologics has raised $19.14M. It was founded in 2020.
IMBiologics is a biotechnology company that develops immunomodulatory antibody therapeutics for the treatment of autoimmune diseases and cancer.
AI Layer
Non-AI
IMBiologics Comparables
Compare IMBiologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Navigator Medicines | 88% | |
| Curogen Technology Co., Ltd. | 80% | |
| Salvina Therapeutics AG | 80% |
For institutional investors. Book with your work email.
IMBiologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 24, 2023 | ||||
| Seed | Jan 19, 2021 |
For institutional investors. Book with your work email.
IMBiologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| K2 Investment Partners | Series B |
| Shinhan Venture Investment | Series B |
| Kingo Investment Partners | Series B |
| KB Investment | Series B, Seed |
| Ard Partners | Series B |
| Woori Financial Group | Series B |
| Yuanta Securities | Series B |
For institutional investors. Book with your work email.
IMBiologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.